That big HKEX biotech boom is start­ing to look shaky; Al­ny­lam gets a green light in the UK for patisir­an

→ The boom­ing biotech mar­ket on the Hong Kong ex­change may be over be­fore it ever re­al­ly got start­ed. With trade war ten­sions run­ning high, the ap­petite for risk in Chi­na has sud­den­ly evap­o­rat­ed, send­ing shares of Chi­na’s first pre-prof­it biotech to go pub­lic — As­cle­tis — down by 15%. That has the in­vest­ment com­mu­ni­ty par­tic­u­lar­ly ner­vous as in­vestors show signs of pulling way back from their bull­ish track record. So far there are two biotechs which made the HKEX leap, in­clud­ing BeiGene with its whop­ping $903 mil­lion sec­ondary.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER